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Abstract
Backgrounds: To determine the true incidence of hGISA/GISA and its consequent clinical impact,
methods must be defined that will reliably and reproducibly discriminate these resistant phenotypes
from vancomycin susceptible S. aureus (VSSA).
Methods: This study assessed and compared the ability of eight Dutch laboratories under blinded
conditions to discriminate VSSA from hGISA/GISA phenotypes and the intra- and inter-laboratory
reproducibility of agar screening plates and the Etest method. A total of 25 blinded and unique
strains (10 VSSA, 9 hGISA and 6 GISA) were categorized by the PAP-AUC method and PFGE typed
to eliminate clonal duplication. All strains were deliberately added in quadruplets to evaluate intra-
laboratory variability and reproducibility of the methods. Strains were tested using three agar
screening methods, Brain Heart Infusion agar (BHI) + 6 µg/ml vancomycin, Mueller Hinton agar
(MH) + 5 µg/ml vancomycin and MH + 5 µg/ml teicoplanin) and the Etest macromethod using a 2
McFarland inoculum.
Results and Discussion: The ability to detect the hGISA/GISA phenotypes varied significantly
between methods and phenotypes. BHI vancomycin and MH vancomycin agar screens lacked the
Published: 24 September 2007
Annals of Clinical Microbiology and Antimicrobials 2007, 6:9 doi:10.1186/1476-0711-6-9
Received: 17 August 2007
Accepted: 24 September 2007
This article is available from: http://www.ann-clinmicrob.com/content/6/1/9
© 2007 Voss et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Annals of Clinical Microbiology and Antimicrobials 2007, 6:9 http://www.ann-clinmicrob.com/content/6/1/9
Page 2 of 5
(page number not for citation purposes)
ability to detect hGISA. The MH teicoplanin agar screen was more sensitive but still inferior to
Etest that had a sensitivity of 98.5% and 99.5%, for hGISA and GISA, respectively. Intra- and inter-
laboratory reproducibility varied between methods with poorest performance seen with BHI
vancomycin.
Conclusion: This is the first multi-center blinded study to be undertaken evaluating various
methods to detect GISA and hGISA. These data showed that the ability of clinical laboratories to
detect GISA and hGISA varied considerably, and that screening plates with vancomycin have a poor
performance in detecting hGISA.
Background
Since the advent of the first glycopeptide intermediately
susceptible S. aureus (GISA) and its heterogeneous variant
(hGISA) in 1997, debate still ensues as to their clinical sig-
nificance [1-9]. This perhaps has been compounded by
the discovery of the vanA-mediated glycopeptide resistant
S. aureus from the US where the glycopeptide minimum
inhibitory concentrations are demonstrably higher and
testing issues are also present, but less problematic
[10,11]. However, the detection of GISA and hGISA are
hampered by the insensitivity of the basic format of stand-
ard methods for capturing these phenotypes. Seven years
after the publication of Mu50 (GISA) and Mu3 (hGISA),
very little has been resolved as to which methods are the
most reliable and reproducible. This in part is due to the
different definitions ascribed to GISA and hGISA that are
subject to methodological differences and variations in
(clinical) breakpoints and cut-off values [12,13]. Whilst
GISA has a more "homogeneous" resistant population
resulting in a higher, stable (thus more reproducible) van-
comycin MIC, h-GISA expresses the resistance at approxi-
mately 1/106 of the native population thereby eluding
detection by conventional methods. However, strains test-
ing positive by these methods share phenotypic character-
istics such as a thickened looser cross-linked cell wall with
glycopeptide intermediate S. aureus (GISA) [14-16]. Thus,
it is possible that hGISA and GISA strains represent the
extremes of a common phenotype conferring reduced sus-
ceptibility to glycopeptides.
Controlled studies have shown that GISA strains inhibited
by a higher vancomycin MIC value are more frequently
associated with clinical failures than VSSA. In contrast, the
clinical relevance of h-GISA remains controversial. How-
ever, numerous case reports have associated hGISA with a
poor response to glycopeptide therapy but studies of their
clinical significance have been hampered by difficulties in
detecting these strains in the diagnostic laboratory and a
lack of confirmatory tests. However, a recent observa-
tional study comparing the clinical features of bacterae-
mia due to hGISA (defined by population analysis
profiles – area under the curve [PAP-AUC ratio]) and fully
vancomycin susceptible MRSA found that hGISA infec-
tion was associated with significantly longer time to defer-
vescence (mean 35 vs 2.9 days), and duration of
bacteraemia (mean 35 vs. 6.4 days), and a non-significant
increase in length of hospital stay (107 vs 37 days) [17].
Clinical failure of vancomycin treatment (defined as fever
and bacteraemia >7 days into vancomycin therapy)
occurred in 100% (5/5) hGISA cases compared to 2.1%
(1/48) MRSA cases.
Studies of the prevalence of GISA and hGISA have also
suffered from various non-standardized methods for
detection and confirmation of these strains so that inter-
country frequencies differ significantly. These differences
may reflect genuine geographical variation but are likely
to be due to methodological inconsistencies. To facilitate
the detection of GISA and in particular hGISA, methods
have been proposed where media, inoculum, and period
of incubation have been altered [5,18-20]. These include
the antibiotic gradient plate, agar screening plates, Etest,
population studies (PS) and population analysis profiles
– area under the curve assays (PAP-AUC) [21,22]. The
most reliable of these is the PAP-AUC; however, it is both
specialized and labor intensive. The implementation of
these methods for detecting resistance will depend on
their intra- and inter-laboratory reproducibility. We
describe herein the first multi-center blinded study com-
paring the reliability of four screening methods in an
eight-center setting; namely, to assess and compare the
inter-laboratory reproducibility of three "agar screening
plates" and the Etest "macromethod" in discriminating
VSSA from hGISA/GISA phenotypes.
Methods
GISA and h-GISA strains
The study included an international collection of 25
unique strains composed of 10 VSSA, 9 hGISA and 6 GISA
as determined by PAP-AUC ratio as previously described
[22]. The strains used represented the five major hospital
lineages as previously described [6]. All strains were delib-
erately added in quadruplets to evaluate intra-laboratory
variability and reproducibility of the methods. Each of the
eight participating laboratories received 100 "numbered"
isolates. Investigators were blinded with regard to the iso-
lates' phenotype and were unaware that the collection
contained replicates.Annals of Clinical Microbiology and Antimicrobials 2007, 6:9 http://www.ann-clinmicrob.com/content/6/1/9
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Agar antibiotic screening plates
Laboratories were asked to perform three screening meth-
ods. The first utilized Brain Heart Infusion (BHI) (Becton
Dickinson, Cockeysville, Md.) agar supplemented with 6
µg/ml of vancomycin (BHI-van) [16]. The other two agar-
screening media were prepared in a similar manner as the
BHI medium. All media were centrally supplied. They
consisted of Mueller Hinton agar (MH- Becton Dickinson,
Cockeysville, Md.) with vancomycin (5 µg/ml) (MH-van)
and with teicoplanin (5 µg/ml) (MH-teico), respectively
[19,23]. Inoculum was prepared as previously described.
10 µl of the inoculum suspension was used for spot inoc-
ulation of the agar screening plates. Plates were incubated
at 35°C for 18 and 40 hours. Growth was reported after
both 24 and 48 hours.
Etest macromethod
The Etest macromethod for hGISA/GISA testing as recom-
mended by the manufacturer was used as previously
described [20]. Essentially, numerous isolated colonies
from an overnight agar culture were suspended into MH
broth to achieve a turbidity corresponding to 2 McFar-
land. 100 µl of the inoculum suspension were pipetted
onto a standard BHI agar plate and streaked out evenly
and then left to dry completely. Etest vancomycin and
teicoplanin MIC gradient strips (AB BIODISK, Solna, Swe-
den) were then applied and the plates incubated at 35°C
and read at 24 and 48 hours independently by two tech-
nicians. The point of complete inhibition of all growth,
including hazes, microcolonies and isolated colonies in
the inhibition ellipse, was used as the end-point. Etest
macromethod results were interpreted as positive for
hGISA/GISA when both vancomycin and teicoplanin
modified MICs were ≥ 8 or when the teicoplanin MIC
alone was ≥ 12. Etest MIC values that fell in between dilu-
tions e.g. 6 µg/ml were not rounded up.
Calculation of sensitivity and specificity
All results were entered into SPSS [24]. The sensitivity (=
the probability that a "positive" case is correctly classified,
thus the false negative rate, and the specificity (= the prob-
ability that a "negative" case is correctly classified, or the
false positive rate) were calculated. Furthermore, Cohen's
kappa was calculated as a measure that expresses the
agreement between the evaluations of two raters when
both are rating the same object. A value of 1 indicates per-
fect agreement. A value of 0 indicates that agreement is no
better than chance.
Results and discussion
Instability of h-GISA phenotype
All GISA and hGISA strains that consistently gave a VSSA
phenotype yet were originally categorized as a GISA/
hGISA as judged by PAP-AUC (ratio >0.9), were re-sent to
the central laboratory to re-confirm their original PAP-
AUC profile. Two strains (a Norwegian hGISA and a
French hGISA) had lost their ability to express the hetero-
geneous form of the resistance (PAP-AUC ratios of 0.82
and 0.75, respectively) for vancomycin and were retro-
spectively excluded from the study. All GISA strains main-
tained their resistant phenotype.
Specificity and sensitivity
The sensitivity and specificity of agar screening methods
and the Etest macromethod are displayed in table 1. The
specificity (i.e. no false positives) of all test methods to
define VSSA varied considerably. MH-van and BHI-van
gave unacceptable values of 58.7% and 68.4%, respec-
tively. In contrast, both MH-teico and Etest macromethod
gave acceptable values of 92.1% and 93.3%, respectively.
The ability of each method to detect GISA and hGISA also
varied considerably (Table 1). The GISA isolates (as
defined by conventional MIC methodology) were virtu-
ally all detected by Etest (sensitivity of 99.5%). The agar
screening methods varied from one another markedly, the
highest sensitivity was MH-teico (95.8%), followed by
BHI-van (85.9%) and the lowest was MH-van (50.8%).
Predictably, the ability of each method to detect h-GISA
varied immensely. Sensitivity values for Etest, MH-teico,
BHI-van and MH-van were 98.5%, 85.0%, 4.5% and
1.0%, respectively. Whilst the ability of Etest, and to a
lesser degree MH-teico, to detect hGISA maybe regarded
as acceptable, the sensitivity values for BHI-van and MH-
van are clearly not.
The inter-laboratory reproducibility of the methods as cal-
culated by Cohen's kappa on the quadruplicate samples
of each strain is depicted in Table 2. Cohen's kappa values
could not be calculated for MH-van for VSSA, MH-van for
hGISA and Etest for GISA due to unbalanced variance of
components. The inter-laboratory reproducibility for
VSSA was acceptable for MH-teico (0.80) and Etest (0.70),
and poor for BHI-van (0.30). For h-GISA, BHI-van also
performed poorly (0.05) compared to MH-teico (0.93)
and Etest (0.88). The reproducibility to detect GISA was
Table 1: Sensitivity and specificity of agar screening plates and 
the Etest macromethod
correctly identified (%)
BHI-van MH-van MH-teico Etest
Overall 
Sensitivity
44.4 25.3 90.3 99.0
Overall 
Specificity
68.4 58.7 92.1 93.3
h-GISA
Sensitivity 4.5 1.0 85.0 98.5
GISA
Sensitivity 85.9 50.5 95.8 99.5Annals of Clinical Microbiology and Antimicrobials 2007, 6:9 http://www.ann-clinmicrob.com/content/6/1/9
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generally better, namely 0.70 for BHI-van, 0.91 for MH-
van, and 0,89 for MH-teico. The overall intra-laboratory
reproducibility was predictably high with values of 0.97,
0.95 and 0.96 for BHI-van, MH-van and MH-teico, respec-
tively.
The marked paucity in controlled studies evaluating the
clinical outcome of patients infected with either hGISA or
GISA may be due to the difficulty in detecting these resist-
ant phenotypes. Much debate still ensues regarding the
clinical significance of GISA and especially hGISA and
which methods are best employed to detect them. Meth-
ods available vary considerably both at an intra- and inter-
country level. For example in the USA, BHI agar screen
containing 6 µg/ml of vancomycin is commercially avail-
able yet teicoplanin is not available, partly because the
drug is not licensed for clinical use in the US. Conse-
quently, most laboratories in the US will preferentially use
BHI-van (6 µg/ml) whereas European laboratories will
prefer MH-teico (5 µg/ml) or BHI with 4 µg/ml vancomy-
cin [2,23]. Inevitably, the variation in prevalence of hGISA
and GISA from these regions may reflect the performance
of the methodologies employed rather than the true inci-
dence of the resistance. It is well known that both hGISA
and GISA are physiologically different from VSSA, pos-
sessing a thicker, less cross-linked cell wall and are usually
nutritionally deficient and considerably slower growing
[8]. Accordingly, standard antimicrobial susceptibility
testing methods are not often appropriate in detecting
these phenotypes and studies with richer media, heavier
inoculum (to detect the low frequency resistance of 1/106)
and extended period of incubation have been docu-
mented as alternative testing conditions. However, such
non-standardized methods are difficult to control and
very few studies have been undertaken examining their
inter- and intra-laboratory variability.
This is the first multi-center blinded hGISA/GISA study
and has highlighted some of strengths and potential defi-
ciencies within the methodological protocol. For instance,
on re-evaluating two strains that gave drastically out-lying
results, two hGISA had "lost" their resistance and reverted
to VSSA on being transferred from the UK to the Nether-
lands clearly demonstrating the instability of some strains
belonging to the hGISA phenotype. The methods chosen
for this study are those that have been proposed by vari-
ous groups as an initial screen to detect hGISA/GISA. The
phenotypic categorization of the strains used in this study
was based on PAP-AUC, a specialized method chosen by
the referral laboratory that is specifically designed to
detect resistant sub-populations that exist with hGISA.
Perhaps not surprisingly, the screening methods chosen
for this study (agar screening plates and Etest mac-
romethod) varied considerably in their ability to detect
hGISA and GISA as judged by the participating laborato-
ries. The poorest performing method under these condi-
tions was MH-van (5 µg/ml) with a sensitivity of 25.3%
and a specificity of 58.7%. Whilst, BHI-van (6 µg/ml) per-
formed better, its sensitivity (44.4%) and specificity
(68.4%) should be deemed as sub-optimal and caution
should be advised when using this screening method.
Both Etest macromethod and MH-teico performed very
well with a sensitivity of 99.0% and 90.3%, respectively.
Although most methods could detect the higher and more
homogeneous level of resistance in GISA (apart from MH-
van), the biggest variation between the methods arose in
detecting hGISA. This in part may be explained by the dif-
ference in inoculum and why using a higher inoculum (2
McFarland) proves the rate of detecting the 1/106 of the
cells expressing this type of resistance.
The inter-laboratory variability of these methods varied
enormously. The poorest of these was BHI-van that gave a
Cohen's kappa value of 0.05 and 0.7 for hGISA and GISA,
respectively. Comparatively, the other methods did much
better and could be regarded as acceptable. The inter-lab-
oratory variation of a screening method is vitally impor-
tant if routine microbiology laboratories are going to be
encouraged to use such methods. Both MH-teico and Etest
performed well, with the latter possessing the highest sen-
sitivity and specificity. Despite the reluctance of some lab-
oratories in implementing the Etest macromethod due to
its non-standardized format, the participating laborato-
ries in this study were able to employ it with very few dif-
ficulties.
Conclusion
The debate on the clinical significance of GISA, and in par-
ticular hGISA is likely to continue for the foreseeable
future [1,6,7]. However, some studies clearly demonstrate
that h-GISA is associated with poorer clinical outcome
and longer hospitalization [17]. The implementation of
non-standardized methods to detect relatively rare and
unusual forms of resistance (i.e. GISA and hGISA) must be
ratified using multi-center data carried out under blind
conditions such as those outlined in this study. The clini-
cal significance of GISA and particularly hGISA can only
be truly assessed by first employing appropriate methods
to detect it.
Table 2: Inter-laboratory reproducibility of agar screening plates 
and Etest macromethod
BHI-van MH-van MH-teico Etest
VSSA 0,29 * 0,80 0,70
h-GISA 0,05 * 0,93 0,88
GISA 0,70 0,91 0,89 *
All isolates 0,97 0,95 0,96 *
* = unable to estimate due to unbalanced variance componentsPublish with BioMed Central    and   every 
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